Eli Lilly & Co. — Sponsor Intelligence | 113 EU Trials

Filter these 113 trials by condition, phase, country and more.

Open in Search →

113 Registered trials

32 Recruiting

75 Completed trials

23 Countries active

85 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 52 Phase II: 26 Phase I/II: 2 Phase IV: 3 Phase I: 17 Phase I (Other): 11 Phase I (FiH): 1 Other: 1

Oversight events:

1 serious breach 14 temporary halts 1 unexpected event 2 corrective measures across 8 trials

View oversight register →

100%

75 of 75 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colitis ulcerative 2 Amyotrophic lateral sclerosis 1 Neurodegenerative disorder 1 Crohn´s disease 1 Crohn's disease 1 Type 2 diabetes mellitus 1

Top IMPs

MIRIKIZUMAB 11 ORFORGLIPRON HEMICALCIUM 8 LY3437943 SODIUM 7 TIRZEPATIDE 7 ABEMACICLIB 6 BARICITINIB 5 LEBRIKIZUMAB 4 DONANEMAB 3 FLORTAUCIPIR (18F) 3 3-((1S,2S)-1-(5-((S)-2,2-DIMETHYLTETRAHYDRO-2H-PYRAN-4-YL)-2-((S)-3-(3-(4-FLUORO-1-METHYL-1H-INDAZOL-5-YL)-2-OXO-2,3-DIHYDRO-1H-IMIDAZOL-1-YL)-2-(4-FLUORO-3,5-DIMETHYLPHENYL)-4-METHYL-4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBONYL)-1H-INDOL-1-YL)-2-METHYLCYCLOPROPYL)-5-OXO-1,2,4-OXADIAZOL-4-IDE HEMICALCIUM 2 FLORBETAPIR (18F) 2 GALCANEZUMAB 2

All trials — page 2

113 total

A Study of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment Recruiting

2025-521947-19-00 Phase I (Other) 2 countries
A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors. Recruiting

2025-521916-20-00 Phase I 2 countries
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting

2024-520210-21-00 Phase III 15 countries MIRIKIZUMAB; TIRZEPATIDE
A Study of LY3457263 Compared to Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Recruiting

2024-520328-27-00 Phase II 2 countries NISOTIROSTIDE; TIRZEPATIDE
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellit… Recruiting

2024-518470-13-00 Phase I (Other) 1 country
A Study of LY4057996 in Healthy Participants and Participants with Type 1 and Type 2 Diabetes (YKAA) Recruiting

2024-519151-28-00 Phase I 1 country
A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors. Recruiting

2024-516440-25-00 Phase I 4 countries
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… Recruiting

2023-508760-29-00 Phase III 11 countries LEBRIKIZUMAB
A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors Recruiting

2024-511238-11-00 Phase I 3 countries
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants wit… Recruiting

2023-510365-10-00 Phase I (Other) 1 country
A Phase 1 study of LOXO-435 in Locally Advanced or Metastatic Solid Tumors with FGFR3 Gene Alterations Recruiting

2022-502755-59-00 Phase I 6 countries
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants with Ulcerative Colitis or Crohn’s Disease (SHINE-ON) Recruiting

2023-506239-14-00 Phase III 10 countries MIRIKIZUMAB
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) Recruiting

2022-502756-31-00 Phase I (FiH) 1 country 2-AMINO-4-[(4AS)-8-CHLORO-10-FLUORO-2,3,4,4A,5,6-HEXAHYDRO-12-OXO-3-(1-OXO-2-PRO…
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X) Recruiting

2023-506131-15-00 Phase III 9 countries BARICITINIB
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5) Ended

2025-522340-40-00 Phase III 2 countries DONANEMAB; FLORBETAPIR (18F); FLORTAUCIPIR (18F)
J2A-MC-GZPO: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2… Ended

2025-521098-14-00 Phase III 2 countries ORFORGLIPRON HEMICALCIUM
A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liv… Ended

2024-520315-40-00 Phase I (Other) 1 country
A Study of Tirzepatide (LY3298176) Compared with Placebo in Adults with Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) Ended

2024-519684-17-00 Phase III 5 countries TIRZEPATIDE
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) A Study of Orforglipron (LY3502970) in Adolescent Partici… Ended

2024-514081-40-00 Phase III 2 countries ORFORGLIPRON HEMICALCIUM
A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors. Ended

2024-516733-12-00 Phase I 5 countries
A Study of Remternetug in Early Alzheimer’s Disease Ended

2024-515656-20-00 Phase III 1 country LY3372993
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA) Ended

2024-515905-25-00 Phase III 2 countries 3-((1S,2S)-1-(5-((S)-2,2-DIMETHYLTETRAHYDRO-2H-PYRAN-4-YL)-2-((S)-3-(3-(4-FLUORO…
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) Ended

2024-511450-49-00 Phase III 2 countries LY3437943 SODIUM; TIRZEPATIDE
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastat… Ended

2023-509867-26-00 Phase I 3 countries

Showing 25–48 of 113 trials

← All sponsors A–Z